Parathyroid Hormone: Physiology and What Research Reports
Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands. A physiology review described it as the principal regulator of extracellular calcium, acting on bone and kidney through the PTH type 1 receptor (PMID 30390810). Other reviews reported that PTH signalling in osteocytes shapes bone remodelling (PMID 30283888), that intermittent versus continuous exposure produces different skeletal effects (PMID 22474638), and that PTH measurement is used during parathyroid surgery (PMID 35953113). This page is educational only.
What Parathyroid Hormone Is
Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands, and a dedicated physiology review described it as the principal endocrine regulator of extracellular calcium, acting on bone and kidney through the PTH type 1 receptor (PTH1R) (Physiology of Parathyroid Hormone). Because PTH is a peptide that binds a class B G protein-coupled receptor, it appears frequently in peptide-pharmacology reading lists: reviews of PTH1R ligands reported that modified peptide agonists and antagonists derived from the hormone have been used as tools to characterise how the receptor is activated and switched off (Characteristics of parathyroid hormone-1 receptor agonists and antagonists). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, testing or treatment.
Where It Is Produced and How It Is Regulated
The same physiology review described secretion from the parathyroid glands as tightly coupled to circulating calcium, with the calcium-sensing mechanism on parathyroid cells and vitamin D metabolism forming a feedback loop that adjusts hormone output (Physiology of Parathyroid Hormone). Reviews of secondary and tertiary hyperparathyroidism reported that chronic kidney disease disturbs this loop, so that mineral and vitamin D abnormalities drive sustained parathyroid stimulation and, over time, gland hyperplasia (Advances in the treatment of secondary and tertiary hyperparathyroidism).
What PTH Does in the Body
Researchers summarising PTH physiology reported that the hormone raises extracellular calcium through coordinated actions on the skeleton and the kidney, with intestinal calcium handling influenced indirectly through active vitamin D (Physiology of Parathyroid Hormone).
Bone and the osteocyte
A review of PTH signalling in osteocytes reported that osteocytes are important PTH1R-expressing targets in bone and that receptor activation in these cells modulates the signals governing bone formation and resorption (Parathyroid Hormone Signaling in Osteocytes). A review of osteoporotic fracture and parathyroid hormone reported that intermittent exposure to PTH produces skeletal effects that differ from those of continuous exposure, which is the basis for interest in PTH-based anabolic approaches to bone (Osteoporotic fracture and parathyroid hormone).
Receptor signalling in detail
Work on endosomal PTH1R signalling reported that the receptor continues to generate cAMP after internalisation into endosomes, so the duration of a signal depends on receptor trafficking as well as on ligand binding at the cell surface (Endosomal parathyroid hormone receptor signaling). Reviews of PTH1R agonists and antagonists reported that different peptide ligands stabilise different receptor conformations, producing short-lived or prolonged responses (Characteristics of parathyroid hormone-1 receptor agonists and antagonists).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freePTHrP: A Closely Related Peptide
Parathyroid hormone-related protein (PTHrP) shares the N-terminal region that engages PTH1R, and a review of PTHrP and malignancy reported that tumour secretion of PTHrP underlies humoral hypercalcaemia of malignancy, a syndrome in which PTH itself is not the driver (Parathyroid hormone-related protein (PTHrP) and malignancy). That distinction matters when reading laboratory reports, because the review described PTHrP-mediated hypercalcaemia as occurring alongside suppressed PTH (Parathyroid hormone-related protein (PTHrP) and malignancy).
How PTH Is Measured and Studied
A review tracing the evolution of intra-operative parathyroid hormone measurement reported that the hormone's short circulating half-life allowed assays to be adapted for use during parathyroid surgery, where sampling before and after gland excision is used to judge whether hyperfunctioning tissue has been removed (Evolution of intra-operative parathyroid hormone and its application in parathyroid surgery). The same review described how assay generations and sampling protocols were refined over time for this application (Evolution of intra-operative parathyroid hormone and its application in parathyroid surgery). In physiology research, reviews reported that interpreting a PTH value requires the simultaneous calcium, phosphate and vitamin D context rather than the hormone level alone (Physiology of Parathyroid Hormone).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appClinical Contexts Where the Term Appears
| Context | What the cited literature reported |
|---|---|
| Primary hyperparathyroidism | A review described primary hyperparathyroidism as a common cause of hypercalcaemia, usually from autonomous parathyroid tissue (Primary hyperparathyroidism). |
| Medical management of primary disease | A review of medical management discussed pharmacologic options considered when surgery is not undertaken, including agents acting on calcium sensing and on bone (Medical management of primary hyperparathyroidism). |
| Secondary and tertiary disease | A review reported that treatment strategies in chronic kidney disease target mineral, vitamin D and receptor pathways, with surgery considered in refractory cases (Advances in the treatment of secondary and tertiary hyperparathyroidism). |
| Hypoparathyroidism | A review of medical hypoparathyroidism described deficient PTH action as producing hypocalcaemia and hyperphosphataemia, managed conventionally with calcium and active vitamin D (Medical Hypoparathyroidism). |
| Children and adolescents | A paediatric review reported that hypoparathyroidism in younger patients has distinct genetic and syndromic causes and requires growth-aware monitoring (Hypoparathyroidism in children and adolescents). |
| Bone and fracture | A review reported interest in PTH-based anabolic strategies for osteoporotic fracture risk based on intermittent exposure (Osteoporotic fracture and parathyroid hormone). |
Why PTH Matters to Peptide Research
Several themes recur in the literature covered above. First, PTH is one of the clearest examples of a peptide hormone whose pattern of exposure changes its biology, since researchers reported that intermittent and continuous exposure differ in their skeletal consequences (Osteoporotic fracture and parathyroid hormone). Second, PTH1R has become a model system for receptor-conformation and trafficking pharmacology, with reports that endosomal signalling prolongs cAMP responses (Endosomal parathyroid hormone receptor signaling) and that engineered peptide ligands behave as agonists or antagonists depending on structure (Characteristics of parathyroid hormone-1 receptor agonists and antagonists). Third, cell-type specificity matters, because osteocyte-focused work reported that a single receptor can produce different outcomes depending on which bone cell expresses it (Parathyroid Hormone Signaling in Osteocytes).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeParathyroid Hormone Pathways: What Studies Report
Reviews in this set discussed the disorders that arise when PTH signalling is too high or too low rather than reporting adverse events of a research protocol. Researchers reported that excess PTH action is associated with hypercalcaemia and skeletal and renal consequences in primary hyperparathyroidism (Primary hyperparathyroidism), and a medical-management review discussed the trade-offs and monitoring needs of non-surgical options (Medical management of primary hyperparathyroidism). On the deficiency side, reviews reported that conventional calcium and active vitamin D therapy does not reproduce normal PTH physiology and requires attention to calcium control and renal complications (Medical Hypoparathyroidism), a point echoed for younger patients (Hypoparathyroidism in children and adolescents). No dosing information is presented here, and nothing on this page describes a protocol; it summarises what the cited papers reported.
References
- Physiology of Parathyroid Hormone (Endocrinology and Metabolism Clinics of North America, 2018)
- Parathyroid Hormone Signaling in Osteocytes (JBMR Plus, 2018)
- Characteristics of parathyroid hormone-1 receptor agonists and antagonists (Future Medicinal Chemistry, 2019)
- Endosomal parathyroid hormone receptor signaling (American Journal of Physiology. Cell Physiology, 2022)
- Parathyroid hormone-related protein (PTHrP) and malignancy (Vitamins and Hormones, 2022)
- Evolution of intra-operative parathyroid hormone and its application in parathyroid surgery (Vitamins and Hormones, 2022)
- Primary hyperparathyroidism (Ulusal Cerrahi Dergisi, 2016)
- Medical management of primary hyperparathyroidism (Archives of Endocrinology and Metabolism, 2022)
- Advances in the treatment of secondary and tertiary hyperparathyroidism (Frontiers in Endocrinology, 2022)
- Medical Hypoparathyroidism (Endocrinology and Metabolism Clinics of North America, 2018)
- Hypoparathyroidism in children and adolescents (Annals of Pediatric Endocrinology & Metabolism, 2023)
- Osteoporotic fracture and parathyroid hormone (World Journal of Orthopedics, 2011)
Frequently asked questions
Is parathyroid hormone a peptide?▾
Yes. A physiology review described PTH as a peptide hormone secreted by the parathyroid glands that regulates extracellular calcium by acting on bone and kidney through the PTH type 1 receptor (PMID 30390810). Because it is a peptide acting at a G protein-coupled receptor, reviews of PTH1R agonists and antagonists used modified peptide ligands to study receptor activation (PMID 30998079).
What does PTH do to bone?▾
Researchers reported that osteocytes express the PTH1R and that receptor activation in these cells modulates the signalling that governs bone formation and resorption (PMID 30283888). A separate review reported that intermittent exposure to PTH produces skeletal effects different from continuous exposure, which is why PTH-based anabolic approaches to osteoporotic fracture risk were studied (PMID 22474638).
How is PTH measured in research and surgery?▾
A review reported that the hormone's short circulating half-life allowed assays to be adapted for intra-operative use, with samples taken before and after gland excision to judge whether hyperfunctioning tissue was removed (PMID 35953113). Physiology reviews noted that a PTH value is interpreted alongside calcium, phosphate and vitamin D rather than alone (PMID 30390810).
What is the difference between PTH and PTHrP?▾
PTHrP shares the receptor-binding N-terminal region of PTH. A review reported that tumour secretion of PTHrP underlies humoral hypercalcaemia of malignancy, a setting in which measured PTH is suppressed rather than elevated (PMID 35953108). Both peptides act through the PTH type 1 receptor, which reviews described as the main mediator of PTH's calcium-regulating actions (PMID 30390810).
What happens when PTH is too high?▾
A review described primary hyperparathyroidism as a common cause of hypercalcaemia arising from autonomously functioning parathyroid tissue (PMID 26985167). A medical-management review discussed non-surgical pharmacologic options and monitoring considerations (PMID 36382758), while a separate review reported that chronic kidney disease drives secondary and tertiary hyperparathyroidism through mineral and vitamin D disturbance (PMID 36561571).
What does the literature report about low PTH activity?▾
A review of medical hypoparathyroidism reported that deficient PTH action produces hypocalcaemia and hyperphosphataemia and that conventional calcium plus active vitamin D therapy does not reproduce normal PTH physiology (PMID 30390814). A paediatric review reported that hypoparathyroidism in children and adolescents has distinct genetic and syndromic causes needing age-appropriate monitoring (PMID 37798892).
Why is PTH1R studied as a model receptor?▾
Researchers reported that PTH1R keeps generating cAMP after internalisation into endosomes, so signal duration depends on receptor trafficking as well as surface binding (PMID 35912987). Reviews of PTH1R ligands reported that peptide analogues stabilise different receptor conformations, yielding short-lived or prolonged responses and making the system useful for pharmacology research (PMID 30998079).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.